Modern views on acetylsalycilic acid in thrombosis/embolia prevention

1. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patienis. BMJ. 2002; 324: 71-86.

2. Antiplatelet Trialist' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 1994; 303: 61-106.

3. Vane J.R., Meade T.W. Second European Stroke prevention Study (ESPS2): clinical and pharmacological implications. J. Neurol. Sci. 1997; 145(2): 123-5.

4. Randomised trial of intravenous, oral aspirin, both, or neither among 17167 cases of suspected acute myocardial infarction: ISIS-2. ISIS 2 (Second International Study of Infarct Survival) Collaboration group. Lancet. 1996 Aug; 349-360.

5. The Dutch TIA Thai Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med 1991; 325: 1261-1266.

6. Hansson L., Zanchetti, Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertention; principal results of Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1988; 351: 1766-1772.

7. Bousser M.G. Antithrombotic strategy in stroke. Thromb. Haemost. 2001; 86: 1-7.

8. Warlow C. Secondary prevention of stroke. Lancet. 192. 339: 724-727.

9. Scrutinio D., Gimminiello С., Marubini E., et al. Tialopidine versus aspirin after myocardial infarction (STAMI) trial. Am. Coll. Cardiol. 2001; 37(5): 1259-65.

10. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischeamic events (CAPRIE). CAPPIE Steering Commit tee Lancet. 1996; 348, 9038: 1329-39.

11. Effect of clopidogrel In addition to aspirin in patients with acute coronary syndromes without ST elevation. The CURE trial investigators. N. Engl. J, Med. 2001; 345494-502.